


Application Ser. No.: 10/613,588  
 Filing Date: July 03, 2003  
 Examiner: Desai, Rita

**Amendment Pursuant to 37 C.F.R. § 1.121**

**IN THE CLAIMS:**

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) A compound of the formula I



(I)

or a stereoisomeric form or a pharmaceutically acceptable salt of the compound of the formula I, wherein

A is  $-(C_1-C_6)\text{-alkyl}$ , in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by

$-O-R^1$  or

$-C(O)-OR^1$ ,

$-C(O)-NR^1R^1$ ,

$-C(O)-NR^1-SO_2R^1$ ,

$-NR^1R^1$ ,

$-CN$ , in which  $R^1$  is

hydrogen,

$-(C_1-C_6)\text{-alkyl}$ ,

$-(C_6-C_{14})\text{aryl}$  or

fluoroalkyl of the formula  $-C_nH_xF_y$  or fluoroalkoxy of the formula  $-OC_nH_xF_y$ , wherein  $n$  is an integer from 1 to 6,  $x$  is an integer from 0 to 12,  $y$  is an integer from 1 to 13 and sum of  $x$  and  $y$  is  $2n + 1$ ,

$-O-R^1$ ,

$-SR^1$ ,

Application Ser. No.: 10/613,588

Filing Date: July 03, 2003

Examiner: Desai, Rita

-S(O)-R<sup>1</sup>

-S(O)<sub>2</sub>-R<sup>1</sup>

-C(O)-OR<sup>1</sup>,

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula

-OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 6, x is an integer from 0 to

12, y is an integer from 1 to 13 and sum of x and y is 2n + 1,

-C(O)-NR<sup>1</sup>R<sup>1</sup>,

-C(O)-NR<sup>1</sup>-SO<sub>2</sub>R<sup>1</sup>,

-NR<sup>1</sup>R<sup>1</sup>,

-CN,

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heteroaryl is unsubstituted or optionally substituted once or more, independently of each other, by R<sup>2</sup>, in which R<sup>2</sup> is

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-OH,

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

halogen,

-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of each other, hydrogen atom or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is 2n + 1,

-CN,

-SR<sup>1</sup>,

-S(O)-R<sup>1</sup>,

-S(O)<sub>2</sub>-R<sup>1</sup> or

-C(O)-NR<sup>1</sup>R<sup>1</sup>,

-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above,

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, wherein

Application Ser. No.: 10/613,588

Filing Date: July 03, 2003

Examiner: Desai, Rita

heteroatoms are selected from N, O and S, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above,

B is a covalent bond,  
-C=CR<sup>1</sup>-,  
—C≡C—  
-O(CH<sub>2</sub>)<sub>a</sub>-, in which a is an integer from 1 to 4,  
O, S, NR<sup>2</sup>, -C(O)-, -NR<sup>2</sup>-C(O)-, -C(O)-NR<sup>2</sup>-, -NR<sup>2</sup>-SO<sub>2</sub>-,  
-SO<sub>2</sub>-NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)-NR<sup>2</sup>-, and R<sup>2</sup> is defined as above, or  
-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, in which alkylene is straight-chain or branched and is optionally substituted, once or more, independently of each other, by R<sup>1</sup>, and R<sup>1</sup> is defined as above,

D is -(C<sub>1</sub>-C<sub>6</sub>)-alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by R<sup>1</sup>, and R<sup>1</sup> is defined as above,

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, and in which heteroaryl is unsubstituted or is substituted once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above,

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above,

-(C<sub>6</sub>-C<sub>14</sub>)-aryl, in which aryl is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above, or

-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above, or

B-D is hydrogen,  
halogen,

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 4, x is

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

an integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is  $2n + 1$ ,

$-(CH_2)_a-Y-R^3$ , in which a is an integer from 1 to 4, Y is O, S,  $NR^2$ , and  $R^3$  is

$-(C_1-C_6)$ -alkyl,  
 $-(C_6-C_{14})$ -aryl,  
 $-(C_3-C_6)$ -cycloalkyl, and

R is hydrogen,  
 $-(C_1-C_6)$ -alkyl, or  
 $-(C_6-C_{14})$ -aryl- $(C_1-C_6)$ -alkyl, in which aryl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above, and

X and Z are identical or different and are, independently of each other selected from:

hydrogen atom,  
 $-(C_1-C_4)$ -alkyl,  
-OH,  
-O- $(C_1-C_4)$ -alkyl),  
halogen,  
fluoroalkyl of the formula  $-C_nH_xF_y$  or fluoroalkoxy of the formula  $-OC_nH_xF_y$ , wherein n is an integer from 1 to 6, x is an integer from 0 to 12, y is an integer from 1 to 13 and sum of x and y is  $2n + 1$ ,  
 $-C(O)-OR^1$ ,  
 $-C(O)-NR^1R^1$ ,  
 $-C(O)-NR^1-SO_2R^1$ ,  
 $-NR^1R^1$ ,  
 $-NR^1-C(O)-NR^1R^1$ ,  
 $-NR^1-C(O)-R^1$ ,  
 $-NR^1-C(O)-OR^1$ ,  
 $-O-C(O)-NR^1R^1$ ,  
 $-CN$ ,  
 $-SR^1$ ,  
 $-S(O)-R^1$ ,  
 $-S(O)_2-R^1$ ,  
 $-S(O)_2-NR^1R^1$ ,  
 $-NR^1-SO_2-R^1$ , in which  $R^1$  is as defined above,

Application Ser. No.: 10/613,588  
 Filing Date: July 03, 2003  
 Examiner: Desai, Rita

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above, or

-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above,

with the proviso that when

A is

- (C<sub>1</sub>-C<sub>6</sub>)-alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by -O-R<sup>1</sup> or -C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, -O-R<sup>1</sup>, in which R<sup>1</sup> is as defined in this proviso, -C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is as defined in this proviso hydrogen or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, or

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heteroaryl is unsubstituted or optionally substituted once or more, independently of each other, by  $R^2$ , in which  $R^2$  is

hydrogen,  
 -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
 -OH,  
 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
 halogen, or

-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of each other, hydrogen atom or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, then:

B is not a covalent bond or -(C<sub>1</sub>-C<sub>4</sub>)-alkylene.

2. (original) A compound of the formula I as claimed in claim 1, wherein

A is -(C<sub>1</sub>-C<sub>3</sub>)-alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by -O-R<sup>1</sup>, or -C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

hydrogen,  
-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or  
-CF<sub>3</sub>

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula  
-OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 3, x is an integer from 0  
to 6, y is an integer from 1 to 7 and sum of x and y is 2n + 1,

B is a covalent bond or O,

D is phenyl or naphthyl, in which phenyl or naphthyl is unsubstituted  
or substituted, once or more, independently of each other, by R<sup>2</sup>, in  
which R<sup>2</sup> is

fluorine, chlorine or bromine,  
-OH,  
-CF<sub>3</sub>,  
-SR<sup>1</sup>, in which R<sup>1</sup> is defined as above,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl

-O-(C<sub>1</sub>-C<sub>2</sub>)-alkyl or  
-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of

each other, hydrogen atom or -(C<sub>1</sub>-C<sub>3</sub>)-alkyl,  
heteroaryl selected from the group consisting of  
pyridyl, furanyl, pyrrolyl, isoxazolyl, benzofuranyl, benzothiophenyl,  
quinolinyl, isoquinolinyl, quinoxalinyl and thiophenyl, in which  
heteroaryl is unsubstituted or substituted, once or more,  
independently of each other, by R<sup>2</sup>, in which R<sup>2</sup> is defined as above  
or

-(C<sub>4</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is  
unsubstituted or substituted, once or more, independently of each  
other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above, or

B-D is ((CH<sub>2</sub>)<sub>a</sub>-Y-R<sup>3</sup>, in which a is an integer from 1 to 2, Y is O and R<sup>3</sup>  
is -(C<sub>1</sub>-C<sub>3</sub>)-alkyl, and

R is hydrogen,

-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or  
-phenyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, and

X and Z are identical or different and are, independently of each  
other, hydrogen, -C(O)-O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -OCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub> or halogen.

3. (original) A compound of the formula 1 as claimed in claim 1, wherein the  
compound of the formula I is selected from the group consisting of:  
5-pyridin-2-yl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

3-methyl-5-(2-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-(3-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
5-phenyl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
1,3-dimethyl-5-(2,6-difluorophenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
1-benzyl-5-cyclohexyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
1-benzyl-5-naphthyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
5-methoxymethyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
7-methoxycarbonyl-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]-isoquinoline,  
7-methoxycarbonyl-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-  
isoquinoline,  
7-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
7-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
6-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
6-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
8-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
8-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
1,3-dimethyl-5-(3-methyl-thiophen-2-yl)-1H-pyrazolo[4,3-c]-isoquinoline,  
3-methyl-5-phenyl-9-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-pyridin-2-yl-9-trifluoromethyl-1H-pyrazolo[4,3-c]-isoquinoline,  
and  
3-methyl-5-(2,3,4,5,6-pentafluoro-phenyl)-1H-pyrazolo[4,3-c]-isoquinoline.

4. (canceled)

5. (withdrawn) A pharmaceutical composition comprising a therapeutically effective content of at least one compound of the formula I as claimed in claim 1 together with a pharmaceutically suitable carrier optionally in

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

combination with a suitable additive, other active compounds and auxiliary substances.


6. (withdrawn) A method of treating a disease condition associated with the increased activity of NIK comprising administering to a patient suffering from said disease condition a therapeutically effective amount of a compound according to claim 1.
7. (withdrawn) The method as claimed in claim 6, wherein the compound is according to claim 2.
8. (withdrawn) The method as claimed in claim 6 wherein said compound is selected from the group consisting of:
- 5-pyridin-2-yl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,
  - 3-methyl-5-(2-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
  - 3-methyl-5-(3-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
  - 3-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,
  - 1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,
  - 5-phenyl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,
  - 1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,
  - 1,3-dimethyl-5-(2,6-difluorophenyl)-1H-pyrazolo[4,3-c]-isoquinoline,
  - 1-benzyl-5-cyclohexyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
  - 1-benzyl-5-naphthyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
  - 5-methoxymethyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,
  - 7-methoxycarbonyl-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]-isoquinoline,
  - 7-methoxycarbonyl-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,
  - 7-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,
  - 7-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,
  - 1,3-dimethyl-5-(3-methyl-thiophen-2-yl)-1H-pyrazolo[4,3-c]-isoquinoline,



Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

3-methyl-5-phenyl-9-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-pyridin-2-yl-9-trifluoromethyl-1H-pyrazolo[4,3-c]-isoquinoline,  
and  
3-methyl-5-(2,3,4,5,6-pentafluoro-phenyl)-1H-pyrazolo[4,3-c]-isoquinoline.

9. (withdrawn) The method as claimed in claim 6, wherein the disease condition is caused due to an inflammatory component.
10. (withdrawn) The method as claimed in claim 6, wherein the diseases are osteoarthritis, rheumatoid arthritis, asthma, irritable bowel disease, Alzheimer's disease, stroke, diabetes, atherosclerosis, multiple sclerosis, rejection reactions on the part of the body against a transplanted organ or rejection reactions on the part of the transplanted organ against the body.
11. (currently amended) A pharmaceutical composition comprising a compound of the formula (I)



or a stereoisomeric form or a pharmaceutically acceptable salt of the compound of the formula I, wherein

A is  $-(C_1-C_6)$ -alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by  
 $-O-R^1$  or

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

-C(O)-OR<sup>1</sup>,  
-C(O)-NR<sup>1</sup>R<sup>1</sup>,  
-C(O)-NR<sup>1</sup>-SO<sub>2</sub>R<sup>1</sup>,  
-NR<sup>1</sup>R<sup>1</sup>,  
-CN, in which R<sup>1</sup> is  
hydrogen,  
-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,  
-(C<sub>6</sub>-C<sub>14</sub>)aryl or  
fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of  
the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1  
to 6, x is an integer from 0 to 12, y is an integer from  
1 to 13 and sum of x and y is 2n + 1,  
-O-R<sup>1</sup>,  
-SR<sup>1</sup>,  
-S(O)-R<sup>1</sup>,  
-S(O)<sub>2</sub>-R<sup>1</sup>,  
-C(O)-OR<sup>1</sup>,  
fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the  
formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 6, x is  
an integer from 0 to 12, y is an integer from 1 to 13 and sum  
of x and y is 2n + 1,  
-C(O)-NR<sup>1</sup>R<sup>1</sup>,  
-C(O)-NR<sup>1</sup>-SO<sub>2</sub>R<sup>1</sup>,  
-NR<sup>1</sup>R<sup>1</sup>,  
-CN,  
monocyclic or polycyclic heteroaryl having from 5 to 14 ring  
members, which contains 1 to 5 heteroatoms as ring  
members, wherein heteroatoms are selected from N, O and  
S, and in which heteroaryl is unsubstituted or optionally

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

substituted once or more, independently of each other, by  
 $R^2$ , in which  $R^2$  is  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-OH,  
-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
halogen,  
-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of  
each other, hydrogen atom or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of  
the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 4, x is an  
integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is  
2n + 1,



-CN,  
-SR<sup>1</sup>,  
-S(O)-R<sup>1</sup>,  
-S(O)<sub>2</sub>-R<sup>1</sup> or  
-C(O)-NR<sup>1</sup>R<sup>1</sup>,

-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is  
unsubstituted or substituted, once or more, independently of each  
other, by  $R^2$ , and  $R^2$  is defined as above,

monocyclic or bicyclic heterocycle having from 5 to 12  
ring members, which contains 1 to 5 heteroatoms as ring members,  
wherein heteroatoms are selected from N, O and S, and in which  
heterocycle is unsubstituted or substituted, once or more,  
independently of each other, by  $R^2$ , and  $R^2$  is defined as above,

B is a covalent bond,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita



$-\text{O}(\text{CH}_2)_a-$ , in which a is an integer from 1 to 4,

O, S,  $\text{NR}^2$ ,  $-\text{C}(\text{O})-$ ,  $-\text{NR}^2-\text{C}(\text{O})-$ ,  $-\text{C}(\text{O})-\text{NR}^2-$ ,  $-\text{NR}^2-\text{SO}_2-$ ,  
 $-\text{SO}_2-\text{NR}^2-$ ,  $-\text{NR}^2-\text{C}(\text{O})-\text{NR}^2-$ , and  $\text{R}^2$  is defined as above, or

$-(\text{C}_1-\text{C}_4)$ -alkylene, in which alkylene is straight-chain or branched and is optionally substituted, once or more, independently of each other, by  $\text{R}^1$ , and  $\text{R}^1$  is defined as above,

D is  $-(\text{C}_1-\text{C}_8)$ -alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by  $\text{R}^1$ , and  $\text{R}^1$  is defined as above,

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heteroaryl is unsubstituted or is substituted once or more, independently of each other, by  $\text{R}^2$ , and  $\text{R}^2$  is defined as above,

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by  $\text{R}^2$ , and  $\text{R}^2$  is defined as above,

$-(\text{C}_6-\text{C}_{14})$ -aryl, in which aryl is unsubstituted or substituted, once or more, independently of each other, by  $\text{R}^2$ , and  $\text{R}^2$  is defined as above, or

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above, or

B-D is hydrogen,  
halogen,

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is 2n + 1,

-(CH<sub>2</sub>)<sub>a</sub>-Y-R<sup>3</sup>, in which a is an integer from 1 to 4, Y is O, S, NR<sup>2</sup>, and R<sup>3</sup> is

-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,  
-(C<sub>6</sub>-C<sub>14</sub>)-aryl,  
-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, and

R is hydrogen,  
-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or  
-(C<sub>6</sub>-C<sub>14</sub>)-aryl-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, in which aryl is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above, and

X and Z are identical or different and are, independently of each other selected from:

hydrogen atom,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-OH,  
-O-(C<sub>1</sub>-C<sub>4</sub>-alkyl),  
halogen,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

fluoroalkyl of the formula  $-C_nH_xF_y$  or fluoroalkoxy of the formula  $-OC_nH_xF_y$ , wherein n is an integer from 1 to 6, x is an integer from 0 to 12, y is an integer from 1 to 13 and sum of x and y is  $2n + 1$ ,

$-C(O)-OR^1$ ,

$-C(O)-NR^1R^1$ ,

$-C(O)-NR^1-SO_2R^1$ ,

$-NR^1R^1$ ,

$-NR^1-C(O)-NR^1R^1$ ,

$-NR^1-C(O)-R^1$ ,

$-NR^1-C(O)-OR^1$ ,

$-O-C(O)-NR^1R^1$ ,

$-CN$ ,

$-SR^1$ ,

$-S(O)-R^1$ ,

$-S(O)_2-R^1$ ,

$-S(O)_2-NR^1R^1$ ,

$-NR^1-SO_2-R^1$ , in which  $R^1$  is as defined above,

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above, or

$-(C_3-C_6)$ -cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above,

with the proviso that when

A is  $-(C_1-C_6)$ -alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

more, independently of each other, by -O-R<sup>1</sup> or -C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-alkyl,

-O-R<sup>1</sup>, in which R<sup>1</sup> is as defined in this proviso,

-C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is as defined in this proviso hydrogen or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, or

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heteroaryl is unsubstituted or optionally substituted once or more, independently of each other, by R<sup>2</sup>, in which R<sup>2</sup> is

hydrogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-OH,

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

halogen, or

-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of each other, hydrogen atom or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, then:

B is not a covalent bond or -(C<sub>1</sub>-C<sub>4</sub>)-alkylene.

12. (original) The composition as claimed in claim 11, wherein

A is -(C<sub>1</sub>-C<sub>3</sub>)-alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by

-O-R<sup>1</sup>, or

-C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is

hydrogen,

-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or

-CF<sub>3</sub>

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 3, x is an

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

integer from 0 to 6, y is an integer from 1 to 7 and sum of x and y is  $2n + 1$ ,

B is a covalent bond or O,

D is phenyl or naphthyl, in which phenyl or naphthyl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , in which  $R^2$  is

fluorine, chlorine or bromine,

-OH,

-CF<sub>3</sub>,

-SR<sup>1</sup>, in which R<sup>1</sup> is defined as above,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl

-O-(C<sub>1</sub>-C<sub>2</sub>)-alkyl or

-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of each other, hydrogen atom or -(C<sub>1</sub>-C<sub>3</sub>)-alkyl,

heteroaryl selected from the group consisting of pyridyl, furanyl, pyrrolyl, isoxazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, quinoxalinyl and thiophenyl, in which heteroaryl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , in which  $R^2$  is defined as above or

-(C<sub>4</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above, or

B-D is  $((CH_2)_a-Y-R^3)$ , in which a is an integer from 1 to 2, Y is O and R<sup>3</sup> is -(C<sub>1</sub>-C<sub>3</sub>)-alkyl, and

R is hydrogen,



Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or  
-phenyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, and

X and Z are identical or different and are, independently of each other, hydrogen, -C(O)-O(C<sub>1</sub>-C<sub>3</sub>)alkyl, -OCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub> or halogen.

13. (original) The composition as claimed in claim 11, wherein the compound of the formula I is selected from the group consisting of:

5-pyridin-2-yl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-(2-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-(3-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
5-phenyl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
1,3-dimethyl-5-(2,6-difluorophenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
1-benzyl-5-cyclohexyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
1-benzyl-5-naphthyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
5-methoxymethyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
7-methoxycarbonyl-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]-isoquinoline,  
7-methoxycarbonyl-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-  
isoquinoline,  
7-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
7-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
6-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
6-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
8-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
8-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
1,3-dimethyl-5-(3-methyl-thiophen-2-yl)-1H-pyrazolo[4,3-c]-isoquinoline,  
3-methyl-5-phenyl-9-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,


Application Ser. No.: 10/613,588

Filing Date: July 03, 2003

Examiner: Desai, Rita

3-methyl-5-pyridin-2-yl-9-trifluoromethyl-1H-pyrazolo[4,3-c]-isoquinoline,  
and  
3-methyl-5-(2,3,4,5,6-pentafluoro-phenyl)-1H-pyrazolo[4,3-c]-isoquinoline.

14. (withdrawn-currently amended) A method of treating a disease condition associated with inflammation comprising administering to a patient suffering from said disease condition a therapeutically effective amount of a compound of formula (I):



or a stereoisomeric form or a pharmaceutically acceptable salt of the compound of the formula I, wherein

A is  $-(C_1-C_6)$ -alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by

$-O-R^1$  or  
 $-C(O)-OR^1$ ,  
 $-C(O)-NR^1R^1$ ,  
 $-C(O)-NR^1-SO_2R^1$ ,  
 $-NR^1R^1$ ,  
 $-CN$ , in which  $R^1$  is  
hydrogen,  
 $-(C_1-C_6)$ -alkyl,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

-(C<sub>6</sub>-C<sub>14</sub>)aryl or

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 6, x is an integer from 0 to 12, y is an integer from 1 to 13 and sum of x and y is 2n + 1,

-O-R<sup>1</sup>,

-SR<sup>1</sup>,

-S(O)-R<sup>1</sup>

-S(O)<sub>2</sub>-R<sup>1</sup>

-C(O)-OR<sup>1</sup>,

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 6, x is an integer from 0 to 12, y is an integer from 1 to 13 and sum of x and y is 2n + 1,

-C(O)-NR<sup>1</sup>R<sup>1</sup>,

-C(O)-NR<sup>1</sup>-SO<sub>2</sub>R<sup>1</sup>,

-NR<sup>1</sup>R<sup>1</sup>,

-CN,

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heteroaryl is unsubstituted or optionally substituted once or more, independently of each other, by

R<sup>2</sup>, in which R<sup>2</sup> is

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-OH,

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

halogen,

-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of each other, hydrogen atom or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

fluoroalkyl of the formula  $-C_nH_xF_y$  or fluoroalkoxy of the formula  $-OC_nH_xF_y$ , wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is  $2n + 1$ ,

-CN,  
-SR<sup>1</sup>,  
-S(O)-R<sup>1</sup>,  
-S(O)<sub>2</sub>-R<sup>1</sup> or  
-C(O)-NR<sup>1</sup>R<sup>1</sup>,

-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above,

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above,

B is a covalent bond,

-C=CR<sup>1</sup>-,

—C≡C—

-O(CH<sub>2</sub>)<sub>a</sub>-, in which a is an integer from 1 to 4,

O, S, NR<sup>2</sup>, -C(O)-, -NR<sup>2</sup>-C(O)-, -C(O)-NR<sup>2</sup>-, -NR<sup>2</sup>-SO<sub>2</sub>-,

-SO<sub>2</sub>-NR<sup>2</sup>-, -NR<sup>2</sup>-C(O)-NR<sup>2</sup>-, and R<sup>2</sup> is defined as above, or

-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, in which alkylene is straight-chain or branched and is optionally substituted, once or more, independently of each other, by R<sup>1</sup>, and R<sup>1</sup> is defined as above,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

D is  $-(C_1-C_6)$ -alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by  $R^1$ , and  $R^1$  is defined as above,

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heteroaryl is unsubstituted or is substituted once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above,

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above,

$-(C_6-C_{14})$ -aryl, in which aryl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above, or

$-(C_3-C_6)$ -cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above, or

B-D is hydrogen,  
halogen,

fluoroalkyl of the formula  $-C_nH_xF_y$  or fluoroalkoxy of the formula  $-OC_nH_xF_y$ , wherein n is an integer from 1 to 4, x is an integer from 0 to 8, y is an integer from 1 to 9 and sum of x and y is  $2n + 1$ ,

Application Ser. No.: 10/613,588

Filing Date: July 03, 2003

Examiner: Desai, Rita

$-(CH_2)_a-Y-R^3$ , in which  $a$  is an integer from 1 to 4,  $Y$  is O, S,  $NR^2$ , and  $R^3$  is

$-(C_1-C_6)$ -alkyl,  
 $-(C_6-C_{14})$ -aryl,  
 $-(C_3-C_6)$ -cycloalkyl, and

$R$  is hydrogen,  
 $-(C_1-C_6)$ -alkyl, or  
 $-(C_6-C_{14})$ -aryl- $-(C_1-C_6)$ -alkyl, in which aryl is unsubstituted or substituted, once or more, independently of each other, by  $R^2$ , and  $R^2$  is defined as above, and

$X$  and  $Z$  are identical or different and are, independently of each other selected from:

hydrogen atom,  
 $-(C_1-C_4)$ -alkyl,  
 $-OH$ ,  
 $-O-(C_1-C_4)$ -alkyl,  
halogen,  
fluoroalkyl of the formula  $-C_nH_xF_y$  or fluoroalkoxy of the formula  $-OC_nH_xF_y$ , wherein  $n$  is an integer from 1 to 6,  $x$  is an integer from 0 to 12,  $y$  is an integer from 1 to 13 and sum of  $x$  and  $y$  is  $2n + 1$ ,  
 $-C(O)-OR^1$ ,  
 $-C(O)-NR^1R^1$ ,  
 $-C(O)-NR^1-SO_2R^1$ ,  
 $-NR^1R^1$ ,  
 $-NR^1-C(O)-NR^1R^1$ ,  
 $-NR^1-C(O)-R^1$ ,  
 $-NR^1-C(O)-OR^1$ ,  
 $-O-C(O)-NR^1R^1$ ,

Application Ser. No.: 10/613,588  
 Filing Date: July 03, 2003  
 Examiner: Desai, Rita

-CN,  
 -SR<sup>1</sup>,  
 -S(O)-R<sup>1</sup>,  
 -S(O)<sub>2</sub>-R<sup>1</sup>,  
 -S(O)<sub>2</sub>-NR<sup>1</sup>R<sup>1</sup>,  
 -NR<sup>1</sup>-SO<sub>2</sub>-R<sup>1</sup>, in which R<sup>1</sup> is as defined above,

monocyclic or bicyclic heterocycle having from 5 to 12 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heterocycle is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above, or

-(C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted, once or more, independently of each other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above,

with the proviso that when

A is

- (C<sub>1</sub>-C<sub>6</sub>)-alkyl, in which alkyl is straight-chain or branched and is optionally substituted, once or more, independently of each other, by -O-R<sup>1</sup> or -C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is hydrogen, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, -O-R<sup>1</sup>, in which R<sup>1</sup> is as defined in this proviso, -C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is as defined in this proviso hydrogen or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, or

monocyclic or polycyclic heteroaryl having from 5 to 14 ring members, which contains 1 to 5 heteroatoms as ring members, wherein heteroatoms are selected from N, O and S, and in which heteroaryl is unsubstituted or optionally substituted once or more, independently of each other, by R<sup>2</sup>, in which R<sup>2</sup> is

- hydrogen,
- (C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- OH,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
halogen, or

-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are,  
independently of each other, hydrogen atom or  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, then:

B is not a covalent bond or -(C<sub>1</sub>-C<sub>4</sub>)-alkylene.

15. (withdrawn) The method as claimed in claim 14 wherein

A is -(C<sub>1</sub>-C<sub>3</sub>)-alkyl, in which alkyl is straight-chain or branched  
and is optionally substituted, once or more, independently of each  
other, by

-O-R<sup>1</sup>, or

-C(O)-OR<sup>1</sup>, in which R<sup>1</sup> is

hydrogen,

-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or

-CF<sub>3</sub>

fluoroalkyl of the formula -C<sub>n</sub>H<sub>x</sub>F<sub>y</sub> or fluoroalkoxy of the  
formula -OC<sub>n</sub>H<sub>x</sub>F<sub>y</sub>, wherein n is an integer from 1 to 3, x is an  
integer from 0 to 6, y is an integer from 1 to 7 and sum of x and y is  
2n + 1,

B is a covalent bond or O,

D is phenyl or naphthyl, in which phenyl or naphthyl is  
unsubstituted or substituted, once or more, independently of each  
other, by R<sup>2</sup>, in which R<sup>2</sup> is

fluorine, chlorine or bromine,

-OH,

-CF<sub>3</sub>,



Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

-SR<sup>1</sup>, in which R<sup>1</sup> is defined as above,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl  
-O-(C<sub>1</sub>-C<sub>2</sub>)-alkyl or  
-N(R<sup>3</sup>)-R<sup>4</sup>, in which R<sup>3</sup> and R<sup>4</sup> are, independently of  
each other, hydrogen atom or -(C<sub>1</sub>-C<sub>3</sub>)-alkyl,

heteroaryl selected from the group consisting of  
pyridyl, furanyl, pyrrolyl, isoxazolyl, benzofuranyl, benzothiophenyl,  
quinoliny, isoquinoliny, quinoxaliny and thiophenyl, in which  
heteroaryl is unsubstituted or substituted, once or more,  
independently of each other, by R<sup>2</sup>, in which R<sup>2</sup> is defined as above or

-(C<sub>4</sub>-C<sub>8</sub>)-cycloalkyl, in which cycloalkyl is  
unsubstituted or substituted, once or more, independently of each  
other, by R<sup>2</sup>, and R<sup>2</sup> is defined as above, or

B-D is ((CH<sub>2</sub>)<sub>a</sub>-Y-R<sup>3</sup>, in which a is an integer from 1 to 2, Y is O and R<sup>3</sup>  
is -(C<sub>1</sub>-C<sub>3</sub>)-alkyl, and

R is hydrogen,

-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, or  
-phenyl-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, and

X and Z are identical or different and are, independently of each other,  
hydrogen, -C(O)-O-(C<sub>1</sub>-C<sub>3</sub>)-alkyl, -OCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub> or halogen.

16. (withdrawn) The method as claimed in claim 14, wherein the compound of  
formula (I) is selected from the group consisting of:  
5-pyridin-2-yl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-(2-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-(3-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

3-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrazolo[4,3-c]isoquinoline,  
1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
5-phenyl-3-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
1,3-dimethyl-5-(3-trifluoromethylphenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
1,3-dimethyl-5-(2,6-difluorophenyl)-1H-pyrazolo[4,3-c]-isoquinoline,  
1-benzyl-5-cyclohexyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
1-benzyl-5-naphthyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
5-methoxymethyl-3-methyl-1H-pyrazolo[4,3-c]-isoquinoline,  
7-methoxycarbonyl-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]-isoquinoline,  
7-methoxycarbonyl-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-  
isoquinoline,  
7-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
7-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
6-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
6-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
8-dimethylamino-3-methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline,  
8-dimethylamino-3-methyl-5-pyridin-2-yl-1H-pyrazolo[4,3-c]-isoquinoline,  
1,3-dimethyl-5-(3-methyl-thiophen-2-yl)-1H-pyrazolo[4,3-c]-isoquinoline,  
3-methyl-5-phenyl-9-trifluoromethyl-1H-pyrazolo[4,3-c]isoquinoline,  
3-methyl-5-pyridin-2-yl-9-trifluoromethyl-1H-pyrazolo[4,3-c]-isoquinoline,  
and  
3-methyl-5-(2,3,4,5,6-pentafluoro-phenyl)-1H-pyrazolo[4,3-c]-isoquinoline.

17. (canceled)

18. (withdrawn) The method as claimed in claim 14, wherein the disease condition is selected from the group consisting of multiple sclerosis, atherosclerosis, inflammatory bowel disease, Alzheimer's disease, stroke and diabetes.

Application Ser. No.: 10/613,588  
Filing Date: July 03, 2003  
Examiner: Desai, Rita

19. (withdrawn) The method as claimed in claim 18, wherein the disease condition is multiple sclerosis.
20. (withdrawn) The method as claimed in claim 18, wherein the disease condition is atherosclerosis.
21. (withdrawn) The method as claimed in claim 18, wherein the disease condition is inflammatory bowel disease.
22. (withdrawn) The method as claimed in claim 18, wherein the disease condition is Alzheimer's disease.
23. (withdrawn) The method as claimed in claim 18, wherein the disease condition is stroke.
24. (withdrawn) The method as claimed in claim 18, wherein the disease condition is diabetes.